Xu Kai, Lang Bin, Fu Bin, Shi Taoping, Wang Baojun, Zhang Xu
1 Department of Urology, Zhujiang Hospital of Southern Medical University , Guangzhou, People's Republic of China .
2 School of Health Sciences, Macao Polytechnic Institute , Macao, People's Republic of China .
J Endourol. 2017 Dec;31(12):1259-1268. doi: 10.1089/end.2017.0525.
Laparoendoscopic single-site surgery (LESS) is increasingly popular in urology. However, data on LESS radical cystectomy (LESS-RC) are immature, and no adequate comparative study has assessed conventional laparoscopic radical cystectomy (CL-RC) vs LESS-RC. The primary aim of this study was to compare efficiency and safety of LESS-RC and CL-RC for patients with bladder urothelial carcinoma (BUC).
A retrospective and case-matched control comparative analysis was performed of patients who underwent LESS-RC (n = 54) and CL-RC (n = 108) from January 2011 to June 2015. Oncologic, complication and perioperative outcomes were collected and evaluated.
LESS-RC vs CL-RC was associated with less estimated blood loss (EBL; median, 270 vs 337.5 mL; p = 0.014), postoperative pain (median, 4.0 vs 6.0 scores; p = 0.001), and shorter convalescence (time to ambulation and oral intake, median, 2.5 vs 3 days; p = 0.002 and 5 vs 6 days; p = 0.004, respectively). No significant differences were noted for LESS-RC and CL-RC regarding the lymph node yield (median: 18 vs 20; p = 0.101). Median follow-up time was 33.5 months (interquartile range [IQR]: 23-41.3 months) and 33 months (IQR: 23-43 months) for the LESS-RC and CL-RC groups, respectively. No significant differences were noted for LESS-RC and CL-RC regarding estimated 24-month overall survival (86.7% vs 88.1%, p = 0.703), cancer-specific survival (88.3% vs 90.9%, p = 0.539), and recurrence-free survival (80.2% vs 87.5%, p = 0.619), even when substratified according to tumor stage (pT or higher) and lymph node status (pN+). Early, late, and 90-day overall complication rates were similar. In multivariate analyses, LESS-RC was not associated with recurrence and worse survival rates, but was associated with 90-day overall complications.
This study demonstrated that LESS-RC and CL-RC have comparable efficiency and safety for patients with BUC. Compared to CL-RC, LESS-RC was with less postoperative pain, lower EBL, and more rapid convalescence, but was associated with 90-day overall complications.
腹腔镜单孔手术(LESS)在泌尿外科越来越受欢迎。然而,关于LESS根治性膀胱切除术(LESS-RC)的数据尚不成熟,且尚无充分的对照研究评估传统腹腔镜根治性膀胱切除术(CL-RC)与LESS-RC的差异。本研究的主要目的是比较LESS-RC和CL-RC治疗膀胱尿路上皮癌(BUC)患者的有效性和安全性。
对2011年1月至2015年6月期间接受LESS-RC(n = 54)和CL-RC(n = 108)的患者进行回顾性病例匹配对照比较分析。收集并评估肿瘤学、并发症和围手术期结果。
LESS-RC与CL-RC相比,估计失血量(EBL)更少(中位数分别为270 vs 337.5 mL;p = 0.014),术后疼痛更轻(中位数评分分别为4.0 vs 6.0;p = 0.001),康复时间更短(下床活动和经口进食时间,中位数分别为2.5 vs 3天;p = 0.002和5 vs 6天;p = 0.004)。LESS-RC和CL-RC在淋巴结获取数量方面无显著差异(中位数:18 vs 20;p = 0.101)。LESS-RC组和CL-RC组的中位随访时间分别为33.5个月(四分位间距[IQR]:23 - 41.3个月)和33个月(IQR:23 - 43个月)。LESS-RC和CL-RC在估计的24个月总生存率(86.7% vs 88.1%,p = 0.703)、癌症特异性生存率(88.3% vs 90.9%,p = 0.539)和无复发生存率(80.2% vs 87.5%,p = 0.619)方面无显著差异,即使根据肿瘤分期(pT及以上)和淋巴结状态(pN+)进行分层分析也是如此。早期、晚期和90天的总体并发症发生率相似。在多因素分析中,LESS-RC与复发和较差的生存率无关,但与90天总体并发症有关。
本研究表明,LESS-RC和CL-RC治疗BUC患者的有效性和安全性相当。与CL-RC相比,LESS-RC术后疼痛更轻、EBL更低、康复更快,但与90天总体并发症有关。